Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Hepatitis C
Interventions
DRUG

daclatasvir

to evaluate the treatment efficacy and safety of the drug in HCV patients

DRUG

asunaprevir

to evaluate the treatment efficacy and safety of the drug in HCV patients

DRUG

Ribavirin

to evaluate the treatment efficacy and safety of the drug in HCV patients

Trial Locations (1)

807

Kaohsiung Medical Universsity, Kaohsiung City

All Listed Sponsors
collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT03004625 - Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV | Biotech Hunter | Biotech Hunter